La Jolla-based Regulus Therapeutics Inc. has announced the pricing of a public offering of 4.5 million shares of its common stock at $9.50 per share. The company expects gross proceeds of $42.8 million.

The offering is expected to close on July 22.

Shares for the publicly traded company, which develops RNA-based therapeutics, dropped about 10 percent following the announcement. Stock traded at $9.66 on July 17 at market close.

— SDBJ Staff Report